Iovance Biotherapeutics Inc

Iovance Soars 43% on Record Amtagvi Sales, Manufacturing Milestone

Iovance shares surged 43% after Q2 revenue beat estimates, driven by Amtagvi sales and a major improvement in gross margin, signaling a manufacturing turning point.

Earnings yesterday

Iovance Soars 39% on Stellar Q2 Amtagvi Sales and Margin Gains

Iovance shares surged 39% after Q2 revenue hit $99.3M, beating guidance by 12.9%, while gross margin more than doubled to 56%. The company is reviewing its 2026 guidance.

Earnings 2d ago

FDA Panel Nod Sparks $763M Value Shift Between Melanoma Drugmakers

Replimune (REPL) soared 107% after an FDA panel endorsed RP1, while Iovance (IOVA) tumbled 13%, shifting $763 million in market value between the two melanoma therapy rivals.

Regulation 6d ago

Replimune Surges 107% as FDA Panel Backs RP1 Despite Data Discrepancies

Replimune shares soared 107% after an FDA panel endorsed RP1's efficacy data, despite conflicting response rates. The FDA decision is expected by August 2.

Analysis Jul 31

Replimune Rockets 131% on FDA Panel Backing for RP1

Replimune shares jumped 131% to $12.50 after an FDA panel voted 10-3 that RP1's efficacy data is interpretable and clinically important, adding nearly $600 million in market value.

Markets Jul 31

Iovance Ends Week Flat as Amtagvi Sales Targets Raise Execution Stakes

Iovance shares ended the week unchanged at $4.99 after hitting a 52-week high of $5.64. The company must nearly double quarterly sales to hit its full-year guidance.

Earnings Jul 25

Iovance Biotherapeutics Shares Surge 18% as Amtagvi Sales Targets Come into Focus

Iovance Biotherapeutics (IOVA) shares climbed 18.2% last week as investors eye the ambitious sales targets for its cancer therapy Amtagvi.

Earnings Jul 19

Iovance Biotherapeutics Soars 18% as Amtagvi Sales Target Nears

Iovance Biotherapeutics (IOVA) shares jumped 18% as investors focus on the upcoming sales test for Amtagvi, with second-quarter revenue guidance of $86-$88 million.

Earnings Jul 18

Iovance Stock Rises on Strong Amtagvi Sales Outlook

Iovance Biotherapeutics gained 10.2% as attention shifts to Amtagvi's second-half sales target of $95.8M-$105.8M per quarter.

Markets Jul 17

Iovance Biotherapeutics Soars 18% on No News, Rally Matches Cash Balance

Iovance Biotherapeutics (NASDAQ:IOVA) shares surged 18% to $4.645, adding ~$319M in market value, matching its cash position. The rally occurred without any new company news, suggesting short covering.

Markets Jul 15

Iovance Biotherapeutics Stock Surges on $89.7 Million ATM Offering

Iovance shares rose 9.4% after launching an $89.65 million ATM stock sale, as investors balance dilution risks against the potential for accelerated Amtagvi revenue growth.

Earnings Jun 23

Replimune Surges 85% on FDA Priority Review for Melanoma Drug

Replimune shares soared 85% after the FDA agreed to a priority review for its melanoma drug RP1, following a previous rejection. New trial data is expected soon.

Markets May 29